X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NATCO PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NATCO PHARMA ASTRAZENECA PHARMA/
NATCO PHARMA
 
P/E (TTM) x 90.9 13.6 667.7% View Chart
P/BV x 20.0 2.8 704.9% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 ASTRAZENECA PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
NATCO PHARMA
Mar-18
ASTRAZENECA PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2781,080 118.3%   
Low Rs883671 131.5%   
Sales per share (Unadj.) Rs228.4592.1 38.6%  
Earnings per share (Unadj.) Rs10.4188.4 5.5%  
Cash flow per share (Unadj.) Rs16.3206.3 7.9%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs98.8833.6 11.8%  
Shares outstanding (eoy) m25.0036.90 67.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.71.5 319.8%   
Avg P/E ratio x104.24.6 2,242.7%  
P/CF ratio (eoy) x66.44.2 1,565.6%  
Price / Book Value ratio x10.91.1 1,041.2%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m27,00832,311 83.6%   
No. of employees `0001.44.8 28.1%   
Total wages/salary Rs m1,5353,256 47.2%   
Avg. sales/employee Rs Th4,210.94,522.5 93.1%   
Avg. wages/employee Rs Th1,132.2674.0 168.0%   
Avg. net profit/employee Rs Th191.11,439.0 13.3%   
INCOME DATA
Net Sales Rs m5,71021,848 26.1%  
Other income Rs m123404 30.3%   
Total revenues Rs m5,83322,252 26.2%   
Gross profit Rs m4639,284 5.0%  
Depreciation Rs m147662 22.3%   
Interest Rs m0154 0.0%   
Profit before tax Rs m4388,872 4.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,920 9.3%   
Profit after tax Rs m2596,952 3.7%  
Gross profit margin %8.142.5 19.1%  
Effective tax rate %40.821.6 188.7%   
Net profit margin %4.531.8 14.3%  
BALANCE SHEET DATA
Current assets Rs m3,20921,307 15.1%   
Current liabilities Rs m2,0705,920 35.0%   
Net working cap to sales %20.070.4 28.3%  
Current ratio x1.63.6 43.1%  
Inventory Days Days7273 98.8%  
Debtors Days Days35107 32.8%  
Net fixed assets Rs m79014,986 5.3%   
Share capital Rs m50369 13.6%   
"Free" reserves Rs m2,41930,353 8.0%   
Net worth Rs m2,46930,760 8.0%   
Long term debt Rs m00-   
Total assets Rs m4,60537,151 12.4%  
Interest coverage xNM58.6-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.6 210.8%   
Return on assets %5.619.1 29.4%  
Return on equity %10.522.6 46.4%  
Return on capital %17.729.3 60.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30010,322 2.9%   
Fx outflow Rs m2,0152,978 67.6%   
Net fx Rs m-1,7157,343 -23.4%   
CASH FLOW
From Operations Rs m884,636 1.9%  
From Investments Rs m-94-11,155 0.8%  
From Financial Activity Rs mNA6,509 0.0%  
Net Cashflow Rs m-6-18 31.7%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 15.7 16.6 94.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   12,856 25,395 50.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   WOCKHARDT  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON   FULFORD INDIA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 160 Points Higher; IT and Healthcare Stocks Witness Buying(Closing)

Indian share markets traded on a positive note most of the day and ended higher. Gains were largely seen in the IT sector and healthcare sector, while capital goods stocks witnessed selling pressure.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

This Smallcap Stock could be the next Page Industries(Profit Hunter)

Jul 2, 2019

The smallcap rebound is taking longer to play out...and that's good news as it gives you more of action time and opportunities to invest in.

The Indian Rating Agency Cleanup Has Begun and this Cheap Stock Could be the Best Bet(The 5 Minute Wrapup)

Jul 2, 2019

The last time this big rating agency was as cheap and out-of-favour as it is today, the stock had corrected by 40% in six months.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 15, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - FDC LTD. COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS